FDA panel: Lilly cancer drug has positive risk/benefit profile

WASHINGTON (Reuters) - An advisory panel to the U.S. Food and Drug Administration effectively supported approval of Eli Lilly & Co's experimental lung cancer drug necitumumab on Thursday but recommended measures be taken to mitigate the drug's risks.